NRIX Insider Trading Activity and SEC Form 4 Filings
NRIX insider trading summary
Over the past 12 months, insiders at Nurix Therapeutics, Inc. (NRIX) reported 45 sales worth $5.1M by 4 insiders and no open-market purchases on SEC Form 4. Net insider selling was $5.1M.
Latest NRIX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Nov 4, 2026 | Houte Hans van | Chief Financial Officer | Sell | $51K (3,300 @ $15.38) |
| Nov 4, 2026 | Houte Hans van | Chief Financial Officer | Sell | $24K (1,469 @ $16.20) |
| Nov 3, 2026 | Christine Ring | Chief Legal Officer | Sell | $158K (6,113 @ $25.83) |
| Nov 2, 2026 | Gwenn Hansen | Chief Scientific Officer | Sell | $39K (1,452 @ $26.80) |
| Nov 2, 2026 | Christine Ring | Chief Legal Officer | Sell | $245K (9,527 @ $25.74) |
| Nov 2, 2026 | Christine Ring | Chief Legal Officer | Sell | $29K (1,075 @ $26.76) |
| Oct 30, 2026 | Houte Hans van | Chief Financial Officer | Sell | $74K (2,834 @ $26.28) |
| Oct 30, 2026 | Gwenn Hansen | Chief Scientific Officer | Sell | $104K (3,957 @ $26.28) |
| Oct 30, 2026 | Christine Ring | Chief Legal Officer | Sell | $104K (3,957 @ $26.28) |
| Oct 15, 2026 | Gwenn Hansen | Chief Scientific Officer | Sell | $36K (1,452 @ $25.00) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.